Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
The Journal of Investigative Dermatology|June 24, 2019
Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous PemphigoidPatricia Colchete Freire, Cristina Herraez Muñoz, Ulla Derhaschnig, et al.
Scientific Reports|January 11, 2018
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testingChristian Schoergenhofer, Michael Schwameis, Christa Firbas, et al.
Analytical and Bioanalytical Chemistry|September 22, 2022
Enriched stable 204Pb as tracer at ultra-low levels in clinical investigationsJohanna Irrgeher, Thomas Berger, Anastassiya Tchaikovsky, et al.
Haematologica|November 25, 2021
The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trialKatarina D Kovacevic, Jürgen Grafeneder, Christian Schörgenhofer, et al.
Allergy|March 2, 2026
Effect of Intramuscular Adrenaline on Histamine-Induced Hypotension: A Randomised Placebo-Controlled Pilot TrialMatthias Weiss-Tessbach, Al Medina Dizdarevic, Thorsten Bischof, et al.
Antimicrobial Agents and Chemotherapy|May 30, 2019
Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy VolunteersZoltan Magyarics, Fraser Leslie, Johann Bartko, et al.
Eclinicalmedicine|January 26, 2024
A randomized, double-blind study on the safety and immunogenicity of rTSST-1 variant vaccine: phase 2 resultsChristian Schoergenhofer, Georg Gelbenegger, Dzenita Hasanacevic, et al.
Vaccine|June 30, 2009
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis CHeiner Wedemeyer, Elisabeth Schuller, Verena Schlaphoff, et al.
Blood|September 15, 2022
The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia ACihan Ay, Katarina D Kovacevic, Daniel Kraemmer, et al.
Trials|January 13, 2019
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trialFarsad Eskandary, Michael Dürr, Klemens Budde, et al.
Pageof 5